SCYNEXIS, Inc. to Present at Jefferies 2015 Antibiotic Summit

Download as PDF

RESEARCH TRIANGLE PARK, N.C., March 12, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that members of the SCYNEXIS executive management team will present at the Jefferies 2015 Antibiotic Summit hosted by Eun Yang at the Jefferies Offices in New York City on Wednesday, March 18, 2015, at 2:10 p.m. ET.

About SCYNEXIS, Inc.

SCYNEXIS is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. For more information, visit www.scynexis.com.

CONTACT: Company
         Chuck Osborne
         Chief Financial Officer
         Tel: 919-544-8600
         E-mail: chuck.osborne@scynexis.com

         Investor Relations
         Jillian Connell
         The Trout Group
         Tel: 646-378-2956
         Email: jconnell@troutgroup.com

         Media Relations
         Heather Savelle
         MacDougall Biomedical Communications
         Tel: 781-235-3060
         E-mail: hsavelle@macbiocom.com
Source: SCYNEXIS, Inc.

Released March 12, 2015